ANZCTR search results

This prospective observational study aims to evaluate bedside two-zone lower limb compression point-of-care ultrasound (POCUS) for the detection of deep vein thrombosis (DVT) in critically ill adults.

The current study aims to address a major gap in care for people with diabetes distress (DD). By conducting a pragmatic randomised controlled trial, the goal is to compare three models of care for people with DD: i) SMOC (recommend GP to refer patient to a psychologist via the mental health care plan) ii) IMOC (individual assessment and management of DD by a DM-informed psychologist) and iii) GMOC (6-session behavioural therapy program delivered via Virtual Care group by DM-informed psychologist and diabetes educator; 3-6 participants per group). Specifically, the study aims to determine the comparative efficacy of GMOC, IMOC and SMOC in improving DD, glycaemic control and reducing hospitalisations in patients with T1DM and DD. The cost effectiveness of each Model of Care will also be examined. The research will generate new knowledge and evidence regarding sustainable models of care addressing an urgent clinical need, as diabetes places an increasing burden on our health system.

Working closely with industry and education stakeholders, this project will generate vital evidence regarding the potential benefits of green spaces for social and emotional well-being, nature connection, and school enjoyment among students and nature connection and occupational well-being/engagement among staff. It will also explore barriers and facilitators to green space innovation and provide insights on the processes of co-designing, adopting and implementing greening. This project will address current gaps in the field by assessing the impacts of co-designed school greening interventions at both specialist and mainstream primary schools. Specialist schools focus on vulnerable communities and are an over-looked setting. This research is also novel in its inclusion of both indoor and outdoor greening and a focus on the impacts of greening for both students and school staff. Finally, it will foster an understanding of the real-world implications of real-world retrofitted greening interventions at multiple schools, enabling the production of practical and policy-relevant greening recommendations for both specialist and mainstream schools.

This study is testing a smartphone app called Perx, designed to help people with cognitive decline and their caregivers manage daily health and wellbeing tasks. Participants will use the app to track tasks like taking medications, attending appointments, and completing optional wellbeing activities. Caregivers will also have access to supportive content developed with dementia specialists. The study aims to understand enrollment feasibility, how engaged participants are, and whether it helps with daily routines and adherence to health tasks. Insights from this pilot will help improve the app and inform future studies to better support people living with cognitive changes and their caregivers.

What the study is about: This study will evaluate whether surovatamig, a novel CD19 × CD3 bispecific T-cell engager, can improve outcomes for people with previously untreated, limited-stage nodal follicular lymphoma (FL). The trial will compare surovatamig with the current standard of care: involved-site radiotherapy (ISRT) with or without rituximab. The aim is to determine whether surovatamig can produce deeper and more durable responses, reduce the risk of disease relapse, and improve event-free survival. Who is it for: This study is for adults aged 18 years or older who have: 1. Histologically confirmed classical follicular lymphoma (Grade 1–3a), Ann Arbor stage I or II nodal, non-bulky disease ( less or equal to 7 cm) 2. PET-positive, measurable disease 3. No prior lymphoma-directed therapy Study details: This is an international, Phase III randomised clinical trial. Participants will be randomised 1:1 on either Surovatamig (6 doses over 12 weeks using a triple step-up dosing schedule) or to the standard of care treatment (Involved-Site Radiotherapy (24 Gy) with or without 6 doses of rituximab, according to each site's predefined standard). Participants will be followed up for 10 years after treatment to assess long-term outcomes. A total of 168 participants will be enrolled across Australia, New Zealand, the United Kingdom, Ireland and Nordic countries. Of these, 60 participants are expected from Australian and New Zealand sites. What is hoped from it: If successful, surovatamig could represent a new standard of care for patients with early-stage nodal follicular lymphoma that is highly effective, well-tolerated, non-radiation frontline option for patients with limited-stage FL.

The CAMAS study is a prospective, longitudinal observational cohort study examining the effects of long-term anaerobic exercise on myocardial structure and function. Adults with predominantly anaerobic gym training are compared with individuals undertaking predominantly aerobic exercise using cardiac magnetic resonance imaging (CMR) and electrocardiography. Blood samples are collected for exploratory molecular analyses where funding permits. Participants are followed annually for up to ten years to document cardiac diagnoses and cardiovascular events. The study aims to identify imaging-based phenotypes associated with anaerobic exercise and potential cardiovascular risk.

This study aims to determine the feasibility of implementing strategies (PTX Implementation Strategy Tollkit) designed to encourage physiotherapists to use recommended sets of exercises (via freely available online software: physiotherapyexercises.com - PTX) and to provide patients with copies of their exercises. This study is a pilot study for a larger, nationwide trial that will test the effectiveness of the PTX Implementation Strategy Toolkit to promote the use of PTX to promote physiotherapists to (i) use recommended sets of exercises available through the PTX software, and (ii) provide patients with copies of their exercises.

The aim of this study is to see if the detrimental cognitive effects of 36 hours of sleep deprivation can be offset by applying slow wave oscillations induced by non-invasive brain stimulation to mimic the effects of slow wave sleep. The study will target healthy adults. Effects will be compared to sham stimulation and a brief nap. It is hypothesised that slow wave brain stimulation will protect the brain from the detrimental effects of sleep deprivation, and will provide similar benefits to that provided by a brief nap.

This study will enrol participants 6 months of age through age 13 with molluscum contagiosum (MC) across up to 6 sites in Australia. Participants will be randomly placed into one of two groups in a 2:1 ratio. This means twice as many children will receive the study treatment (Zabalafin Hydrogel) compared with those who receive the placebo. The purpose of the study is to see how well Zabalafin Hydrogel 9.5% works and how safe it is when used twice a day to treat MC. The main goal is to find out how many participants have more than 75% of their MC cleared by Week 16.

There is evidence that the deepest form of sleep, slow wave sleep, may be a critical target for maintaining cognitive function and reducing the risk of developing Alzheimer’s disease. One way deep sleep may affect the risk of Alzheimer’s disease risk is by helping the brain and body clear out chemicals. We aim to test whether improving deep sleep using an at home EEG device helps with this clearance, and explore what health and lifestyles factors might influence the results, including brain toxin and volume level as measured using MR-PET scans..